STAT3 inhibitors have been shown to have anti-proliferative and pro-apoptotic effects in vitro and in vivo in several cancers [15, 16] and have entered clinical trials (NCI Glioblastoma Clinical Trial No. NCT00696176 and [17]). This evidence concerns the gene STAT3 and cancer.